Relmada Therapeutics (RLMD) risk factors

53 risks, 6 new, 7 dropped, 13 reworded since the prior year. Relmada terminated the development of its primary drug candidate, esmethadone, after the Phase 3 Reliance II study failed to meet its primary efficacy endpoint. The company also dropped psilocybin development for metabolic disease and faced a Nasdaq minimum bid price deficiency. Net operating loss carryforwards increased to approximately $246,410,000 for Federal and $2,719,000 for State.

54 risks. Relmada Therapeutics paused its primary drug candidate esmethadone and pivoted to early-stage candidates NDV-01 and Sepranolone.